CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 272 enrolled
Drug / intervention
SmofKabiven Peripheral +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03792087
NCT03792087Phase 3Completed

Efficacy & Safety of SmofKabiven Peripheral vs Compounded Emulsion: A Randomized, Active-Controlled, Open-Labelled, Multi-Centre Study in Adult Surgical Patients Requiring Parenteral Nutrition

Fresenius Kabi·interventional·Posted Jan 3, 2019·Updated Aug 2, 2021

In Brief

A Phase 3 clinical trial evaluating SmofKabiven Peripheral and Hospital compounded emulsion for Parenteral Feeding and Surgery. Completed, enrolled 272 participants across 5 sites.

Detailed Summary

The present protocol describes a randomized, open-labelled study in which either SmofKabiven Peripheral or a hospital compounded control Parenteral Nutrition (PN) regimen will be given to adult surgical patients for 5 consecutive days. As serum prealbumin is a well-established surrogate efficacy parameter reflecting the patient´s nutritional status, the absolute change of the serum prealbumin level at the day of the final study visit compared to baseline will represent the primary efficacy parameter in the present study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
CollaboratorsParexel

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJan 3, 2019
Enrollment StartDec 21, 2017
Primary CompletionDec 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.5 years ago

Interventions

SmofKabiven Peripheraldrug

Total Parenteral Nutrition

Hospital compounded emulsiondrug

Total Parenteral Nutrition